Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.
Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Presents at Jefferies London Healthcare Conference 2025 Transcript
Roivant Sciences Ltd. ( ROIV ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Matthew Gline - CEO & Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good afternoon.
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced
ROIV's holding-company model with its Vants continues creating shareholder value. They then recycle M&A and partnership proceeds into late-stage assets. ROIV focuses on autoimmune and rare-disease drug programs. Recent promising Phase 3 data for DM with Brepocitinib have helped the stock appreciate. Brepocitinib could tap into a sizeable TAM over time, and its NDA filing for DM is expected by 1H2026. Plus, it can target NIU and CS.
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27.
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participants Jason Gerberry - BofA Securities, Research Division Presentation Jason Gerberry BofA Securities, Research Division We're at time.
Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Matthew Gline - CEO & Director Stephanie Lee Griffin - Vice President of Special Projects Conference Call Participants Corinne Johnson - Goldman Sachs Group, Inc., Research Division David Reed Risinger - Leerink Partners LLC, Research Division Douglas Dylan Tsao - H.C.
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23.
Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q4 2024 Earnings Conference Call May 29, 2025 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Richard Pulik - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Samuel Slutsky - LifeSci Capital Yatin Suneja - Guggenheim Securities Douglas Tsao - H.C.
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.16.
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant's brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs.
All You Need to Know About Montes Archimedes Acquisition (ROIV) Rating Upgrade to Buy
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
